New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
09:00 EDTGILDGilead price target raised to $90 from $84 at Argus
Argus increased its price target on Gilead after the company reported Q4 sales that the firm views as strong, but did not include any sales from Sovaldi in its 2014 guidance. The firm still expects the company to obtain revenue from Sovaldi ,and it keeps a Buy rating on the stock.
News For GILD From The Last 14 Days
Check below for free stories on GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent GILD news | >>
April 10, 2014
13:12 EDTGILDGilead volatility increases on wide price movement
Subscribe for More Information
11:44 EDTGILDStocks with call strike movement; PCLN GILD
Subscribe for More Information
11:42 EDTGILDReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
07:24 EDTGILDInternational Society for Heart & Lung Transplantation to hold annual meeting
Subscribe for More Information
05:37 EDTGILDGilead announces Phase 2 results for investigational sofosbuvir-based regimens
Gilead Sciences announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir, or SOF, for the treatment of chronic hepatitis C virus, or HCV, infection. The first study, ELECTRON2, is an ongoing, open-label Phase 2 clinical trial evaluating a once-daily fixed-dose combination of SOF 400 mg and the NS5A inhibitor ledipasvir, or LDV, 90 mg, with and without ribavirin, or RBV, twice-daily, among HCV-infected patient populations. In this study, 100% of treatment-na´ve genotype 3 patients receiving 12 weeks of LDV/SOF plus RBV and 64% of treatment-na´ve genotype 3 patients receiving 12 weeks of LDV/SOF without RBV achieved a sustained virologic response 12 weeks after completing therapy. Among genotype 1-infected patients who had failed prior treatment with SOF plus RBV, 100% achieved SVR12 following 12 weeks of LDV/SOF plus RBV. Additionally, 65% of genotype 1-infected patients with decompensated or Child-Turcotte-Pugh Class B cirrhosis receiving 12 weeks of LDV/SOF without RBV achieved SVR12. LDV/SOF with and without RBV was well-tolerated, including among patients with more advanced liver disease. A second study, Study GS-US-342-0102, is an ongoing randomized Phase 2 clinical trial in which treatment-na´ve, non-cirrhotic patients with genotypes 1-6 HCV infection received a 12-week course of SOF plus the pan-genotypic NS5A inhibitor GS-5816. Patients received SOF 400 mg and either GS-5816 25 mg or GS-5816 100 mg. In this study, 94.8% of patients receiving the 25 mg dose of GS-5816 and 96.1% of patients receiving the 100 mg dose achieved SVR12.
05:32 EDTGILDGilead announces results from study of Sovaldi
Subscribe for More Information
April 9, 2014
16:00 EDTGILDOptions Update; April 9, 2014
Subscribe for More Information
11:51 EDTGILDStocks with call strike movement; AAL GILD
American Airlines (ALL) August 44 call option implied volatility increased 4% to 39, Gilead (GILD) August 80 call option implied volatility decreased 2% to 34 according to IVolatility.
11:43 EDTGILDGilead defended by analysts after recent pullback
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
08:41 EDTGILDAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.
07:56 EDTGILDGilead poised for strong earnings, says RW Baird
Subscribe for More Information
07:23 EDTGILDEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
April 7, 2014
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
08:31 EDTGILDGilead announecs FDA priority review designation for Ledipasvir/Sofosbuvir
Gilead Sciences announced that the U.S. Food and Drug Administration has granted priority review to the companyĺs New Drug Application for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead filed the NDA for LDV/SOF on February 10, and the FDA has set a target action date under the Prescription Drug User Fee Act of October 10. The FDA has also assigned LDV/SOF a Breakthrough Therapy designation.
April 4, 2014
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA MU GNK AMZN FB GILD MA NFLX
April 3, 2014
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
April 2, 2014
16:32 EDTGILDGilead Phase 3 sofosbuvir study meets primary efficacy endpoint
Gilead Sciences announced topline results from a Phase 3 clinical trial in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin for the treatment of genotype 2 chronic hepatitis C virus infection. The study met its primary efficacy endpoint of superiority compared to a predefined historical control sustained virologic response rate. In the study, 97% of genotype 2 HCV-infected patients receiving 12 weeks of an all-oral regimen of sofosbuvir plus RBV achieved a sustained virologic response 12 weeks after completing therapy. Based on these trial results, Gilead anticipates submitting a New Drug Application for sofosbuvir to the Japanese Pharmaceutical and Medical Devices Agency by mid-2014
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
06:21 EDTGILDGilead shares attractive at current levels, says Citigroup
Citigroup views shares of Gilead as "cheap" at current levels and keeps a Buy rating on the name with a $96 price target. Citi expects Gilead to generate $117B in free cash flow over the next 10 years and have $100B by 2023.
1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use